ClinicalTrials.gg
CompletedNCT02553265CarbiFDUpdated Feb 9, 2022Results posted

Carbidopa for the Treatment of Excessive Blood Pressure Variability

A Phase 2 interventional study of Carbidopa Low-Dose and Placebo in Dysautonomia, Familial and Baroreflex Failure Syndrome, sponsored by NYU Langone Health. Completed at 2 sites in United States. Open to participants aged 10 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
10 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by NYU Langone Health — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · NYU Langone Health.

Enrollment
37th of 39
22 · median 300
Started
2015
with 1 other
Phase 2
3 of 44
none open now
Registered
20th of 44
by date

Among the 44 studies in Hypertension by NYU Langone Health, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 20th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 44 studies in Hypertension by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 10 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by NYU Langone Health, or all of them as a file.
02

Study summary

The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndrome). Funding Source- FDA OOPD.

Read the detailed description

The investigators propose to perform a double-blind randomized trial with a cross over design to compare high dose (600 mg/day) and low dose (300 mg per day) carbidopa blockade with placebo. Patients will be randomly assigned to a high-dose/low-dose/placebo sequence, lowdose/placebo/high-dose sequence or placebo/high-dose/low-dose sequence. Participants will remain on each treatment period for 28-days.

Aim 1: To evaluate the safety and tolerability of carbidopa in FD patients with particular emphasis on the orthostatic fall in blood pressure.

Aim 2: As proof of concept, examine the hemodynamic effects of carbidopa and determine its effects on norepinephrine production, BP variability and paroxysmal hypertension.

Aim 3: In a dose finding study, compare the effects of low (300 mg/day) and high (600 mg/day) dose carbidopa blockade vs. placebo on BP variability and paroxysmal hypertension.

03

Conditions studied

  • Dysautonomia, Familial
  • Baroreflex Failure Syndrome

Browse trials for

Keywords

  • Familial dysautonomia (HSAN III)
  • Norepinephrine
  • Sympathetic nervous system
  • Autonomic nervous system
  • Blood pressure variability
  • Hypertension
  • Carbidopa/Lodosyn
  • Afferent baroreflex failure
  • Clinical trial
04

Who can participate

Ages eligible
10 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients with familial dysautonomia (FD) age 10 or older
  • Unstable blood pressure, defined as:

    • Systolic BP standard deviation >15 mmHg
    • Or coefficient of variation >15%
    • Or documented episodic hypertensive peaks (>140mmHg)
  • Confirmed diagnosis of FD (genetic testing)
  • Providing written (or ascent) to participate in the trial
  • Ability to comply with the requirements of the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients taking monoamine oxidase (MAO)-inhibitors
  • Patients taking: metoclopramide, domperidone, risperidone or other dopamine blockers
  • Patients taking tricyclic antidepressants
  • Patients taking neuroleptic drugs (haloperidol and chlorpromazine)
  • Patients with a known to any component of this drug.
  • Patients with atrial fibrillation, angina or significant abnormality
  • Patients with significant pulmonary, cardiac, liver, renal (creatinine >2.0 mg/ml)
  • Patients who have a significant abnormality on clinical examination that may, in the investigator's opinion might jeopardize their healthy participating in this trial.
  • Women who are pregnant or lactating.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo

    Other: Placebo

  • Experimental
    Low-Dose Carbidopa

    Drug: Carbidopa Low-Dose

  • Active comparator
    High-Dose Carbidopa

    Drug: Carbidopa High-Dose

Interventions

  • DrugCarbidopa Low-Dose

    300 mg/day

    Also known as: Lodosyn ®, DL-α-methyl-α-hydrazino-3, 4-dihydroxyphenyl-propionic acid, HMD, MK-486

  • OtherPlacebo

    A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.

    Also known as: Placebo control pill

  • DrugCarbidopa High-Dose

    600 mg/day

    Also known as: Lodosyn ®, DL-α-methyl-α-hydrazino-3, 4-dihydroxyphenyl-propionic acid, HMD, MK-486

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Reported Adverse Events Related to Study Drug

    Adverse events defined as: a change in a patient's baseline condition including intercurrent illnesses irrespective of the relationship to carbidopa treatment. This will be monitored primarily with phone calls at weekly intervals. In addition, patients will be asked about adverse events while at the office. Patients will also fill a daily diary with a specific prompts to note any adverse events.

    Time frame: Up to 90 days

  2. Number of Participants With Significant Changes in Body Mass That Resulted in Discontinuation From the Study.

    Body mass measured in kg

    Time frame: Up to 90 days

  3. Number of Participants With Abnormal Electrocardiographic Interval Patterns

    Clinically significant changes in the intervals of characteristic electrocardiographic patterns

    Time frame: Up to 90 days

  4. Average Systolic Blood Pressure Variability (Daytime)

    Patients with FD undergo ambulatory BP monitoring while keeping a detailed log of their activities (sleep/meal-times/medications/posture/symptoms). Variability in blood pressure overtime will be measured by the standard deviation during awake hours

    Time frame: up to Week 14

  5. Highest Systolic Blood Pressure

    Maximum blood pressure captured on 24-h ambulatory monitoring

    Time frame: Day 1 of treatment period

  6. Systolic Blood Pressure

    SBP measured in the seated position

    Time frame: up to Week 14

  7. Heart Rate

    Heart rate in the seated position

    Time frame: up to Week 14

  8. Number of Participants Who Displayed Clinical Significant Laboratory Values on CBC or Metabolic Panel

    Clinically significant laboratory values include complete blood count (CMC) and metabolic panel related to treatment with carbidopa

    Time frame: Up to 90 days

  9. Number of Participants Who Displayed Clinically Significant Values in Urine Safety Parameters

    Clinically significant values on urinalysis, urine safety parameters related to treatment with carbidopa

    Time frame: Up to 90 days

Secondary outcomes

  1. Severity of Hypotension During an Active Stand Test

    Lowest blood pressure captured during 3 minutes of standing

    Time frame: up to Week 14

  2. Number of Participants Who Reported Worsening of OH Symptoms or Dropped Out Because of Worsening OH While on Active Study Drug

    Time frame: Up to 90 days

  3. Frequency of Worsening Symptoms Noted in the Patient's Diary

    A tailored questionnaire to examine symptoms over the treatment period and the used of as needed medications. Each day will have a designated page. Since nausea/vomiting and hypertension occur together in FD we will use a diary consisting of a simplified version of the Rhodes Index 44 symptoms of nausea/retching, with items addressing vomiting/throwing up omitted, as most participants will have had anti-reflux surgery to prevent vomiting (fundoplication), graded on a 5-point scale (appendix 2). The diary will also include space to write down any adverse events on a daily basis.

    Time frame: Up to 90 Days

  4. 24-h Urinary Norepinephrine Excretion

    Norepinephrine concentration determined from a 24-hour urine sample in a bottle shielded from light containing preservative. Patients will be instructed to refrigerate their sample and bring it on the morning of their visit in a cool bag.

    Time frame: up to Week 14

  5. Coefficient of Systolic BP Variability (Daytime)

    The measurement of blood pressure variability based on the standard deviation that also takes into account the underlying level of BP.

    Time frame: up to Week 14

  6. Morning Surge in Systolic BP on Awakening From Sleep (24-h)

    The morning surge will be calculated as the difference between the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep and maximum value detected within 2-h of awakening from sleep

    Time frame: up to Week 14

07

Results

Posted Feb 9, 2022

Participant flow

Enrollment
Participant flow — Enrollment
MilestoneLow-Dose Carbidopa, Then Placebo, Then High-Dose CarbidopaHigh-Dose Carbidopa, Then Low-Dose Carbidopa, Then PlaceboPlacebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa
Started976
Completed975
Not completed001
Withdrew: Death001
First Intervention (28 Days)
Participant flow — First Intervention (28 Days)
MilestoneLow-Dose Carbidopa, Then Placebo, Then High-Dose CarbidopaHigh-Dose Carbidopa, Then Low-Dose Carbidopa, Then PlaceboPlacebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa
Started975
Completed874
Not completed101
Withdrew: Adverse event100
Withdrew: Withdrawal by subject001
Second Intervention (28 Days)
Participant flow — Second Intervention (28 Days)
MilestoneLow-Dose Carbidopa, Then Placebo, Then High-Dose CarbidopaHigh-Dose Carbidopa, Then Low-Dose Carbidopa, Then PlaceboPlacebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa
Started874
Completed774
Not completed100
Withdrew: Adverse event100
Third Intervention (28 Days)
Participant flow — Third Intervention (28 Days)
MilestoneLow-Dose Carbidopa, Then Placebo, Then High-Dose CarbidopaHigh-Dose Carbidopa, Then Low-Dose Carbidopa, Then PlaceboPlacebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa
Started774
Completed673
Not completed101
Withdrew: Adverse event100
Withdrew: Lost to follow-up001

Outcome measures

PrimaryNumber of Participants Who Reported Adverse Events Related to Study Drug

Adverse events defined as: a change in a patient's baseline condition including intercurrent illnesses irrespective of the relationship to carbidopa treatment. This will be monitored primarily with phone calls at weekly intervals. In addition, patients will be asked about adverse events while at the office. Patients will also fill a daily diary with a specific prompts to note any adverse events.

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants Who Reported Adverse Events Related to Study Drug
ParticipantsPlaceboLow-Dose CarbidopaHigh-Dose Carbidopa
Number of Participants Who Reported Adverse Events Related to Study Drug000
PrimaryNumber of Participants With Significant Changes in Body Mass That Resulted in Discontinuation From the Study.

Body mass measured in kg

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants With Significant Changes in Body Mass That Resulted in Discontinuation From the Study.
ParticipantsPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Number of Participants With Significant Changes in Body Mass That Resulted in Discontinuation From the Study.000
PrimaryNumber of Participants With Abnormal Electrocardiographic Interval Patterns

Clinically significant changes in the intervals of characteristic electrocardiographic patterns

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiographic Interval Patterns
ParticipantsPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Number of Participants With Abnormal Electrocardiographic Interval Patterns000
PrimaryAverage Systolic Blood Pressure Variability (Daytime)

Patients with FD undergo ambulatory BP monitoring while keeping a detailed log of their activities (sleep/meal-times/medications/posture/symptoms). Variability in blood pressure overtime will be measured by the standard deviation during awake hours

Time frame:
up to Week 14
Reported as:
Mean · mmHg
Average Systolic Blood Pressure Variability (Daytime)
mmHgPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Average Systolic Blood Pressure Variability (Daytime)22.92 ± 6.1318.71 ± 4.8316.92 ± 4.14
PrimaryHighest Systolic Blood Pressure

Maximum blood pressure captured on 24-h ambulatory monitoring

Time frame:
Day 1 of treatment period
Reported as:
Mean · mmHg
Highest Systolic Blood Pressure
mmHgPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Highest Systolic Blood Pressure175 ± 27157 ± 20150 ± 17
PrimarySystolic Blood Pressure

SBP measured in the seated position

Time frame:
up to Week 14
Reported as:
Mean · mmHg
Systolic Blood Pressure
mmHgPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Systolic Blood Pressure126 ± 27126 ± 18126 ± 21
PrimaryHeart Rate

Heart rate in the seated position

Time frame:
up to Week 14
Reported as:
Mean · beats per minute (BPM)
Heart Rate
beats per minute (BPM)PlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Heart Rate76 ± 1172 ± 1378 ± 13
PrimaryNumber of Participants Who Displayed Clinical Significant Laboratory Values on CBC or Metabolic Panel

Clinically significant laboratory values include complete blood count (CMC) and metabolic panel related to treatment with carbidopa

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants Who Displayed Clinical Significant Laboratory Values on CBC or Metabolic Panel
ParticipantsPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Number of Participants Who Displayed Clinical Significant Laboratory Values on CBC or Metabolic Panel000
PrimaryNumber of Participants Who Displayed Clinically Significant Values in Urine Safety Parameters

Clinically significant values on urinalysis, urine safety parameters related to treatment with carbidopa

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants Who Displayed Clinically Significant Values in Urine Safety Parameters
ParticipantsPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Number of Participants Who Displayed Clinically Significant Values in Urine Safety Parameters000
SecondarySeverity of Hypotension During an Active Stand Test

Lowest blood pressure captured during 3 minutes of standing

Time frame:
up to Week 14
Reported as:
Mean · mmHg
Severity of Hypotension During an Active Stand Test
mmHgPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Severity of Hypotension During an Active Stand Test96 ± 2791 ± 2896 ± 24
SecondaryNumber of Participants Who Reported Worsening of OH Symptoms or Dropped Out Because of Worsening OH While on Active Study Drug
Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants Who Reported Worsening of OH Symptoms or Dropped Out Because of Worsening OH While on Active Study Drug
ParticipantsPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Number of Participants Who Reported Worsening of OH Symptoms or Dropped Out Because of Worsening OH While on Active Study Drug000
SecondaryFrequency of Worsening Symptoms Noted in the Patient's Diary

A tailored questionnaire to examine symptoms over the treatment period and the used of as needed medications. Each day will have a designated page. Since nausea/vomiting and hypertension occur together in FD we will use a diary consisting of a simplified version of the Rhodes Index 44 symptoms of nausea/retching, with items addressing vomiting/throwing up omitted, as most participants will have had anti-reflux surgery to prevent vomiting (fundoplication), graded on a 5-point scale (appendix 2). The diary will also include space to write down any adverse events on a daily basis.

Time frame:
Up to 90 Days
Reported as:
Number · symptoms
Frequency of Worsening Symptoms Noted in the Patient's Diary
symptomsPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Frequency of Worsening Symptoms Noted in the Patient's Diary000
Secondary24-h Urinary Norepinephrine Excretion

Norepinephrine concentration determined from a 24-hour urine sample in a bottle shielded from light containing preservative. Patients will be instructed to refrigerate their sample and bring it on the morning of their visit in a cool bag.

Time frame:
up to Week 14
Reported as:
Mean · pg/mL
24-h Urinary Norepinephrine Excretion
pg/mLPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
24-h Urinary Norepinephrine Excretion16 ± 116 ± 38 ± 6
SecondaryCoefficient of Systolic BP Variability (Daytime)

The measurement of blood pressure variability based on the standard deviation that also takes into account the underlying level of BP.

Time frame:
up to Week 14
Reported as:
Mean · mmHg
Coefficient of Systolic BP Variability (Daytime)
mmHgPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Coefficient of Systolic BP Variability (Daytime)19 ± 416 ± 415 ± 3
SecondaryMorning Surge in Systolic BP on Awakening From Sleep (24-h)

The morning surge will be calculated as the difference between the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep and maximum value detected within 2-h of awakening from sleep

Time frame:
up to Week 14
Reported as:
Mean · mmHg
Morning Surge in Systolic BP on Awakening From Sleep (24-h)
mmHgPlaceboHigh-Dose CarbidopaLow-Dose Carbidopa
Morning Surge in Systolic BP on Awakening From Sleep (24-h)44 ± 2419 ± 1120 ± 9

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low-Dose Carbidopa1/16 (6.3%)1/16 (6.3%)4/16 (25%)
High-Dose Carbidopa0/16 (0%)0/16 (0%)3/16 (18.8%)
Placebo0/16 (0%)0/16 (0%)0/16 (0%)
Most frequent serious events
Most frequent serious events
EventLow-Dose CarbidopaHigh-Dose CarbidopaPlacebo
HospitaliztionGeneral disorders1/160/160/16
Most frequent other events
Most frequent other events
EventLow-Dose CarbidopaHigh-Dose CarbidopaPlacebo
DiarrheaGastrointestinal disorders4/160/160/16
SyncopeVascular disorders0/163/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Dose Carbidopa, High Dose Carbidopa, Placebo
Mean28 (13 to 58)
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose Carbidopa, High Dose Carbidopa, Placebo
Female14
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low Dose Carbidopa, High Dose Carbidopa, Placebo
Hispanic or Latino0
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose Carbidopa, High Dose Carbidopa, Placebo
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White22
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Low Dose Carbidopa, High Dose Carbidopa, Placebo
United States22
08

Study locations

2 sites
  • NYU Langone Medical Center, Dyautonomia Center, Suite 9Q
    New York, New York 10016, United States
  • NYU Medical Center
    New York, New York 10016, United States
09

References and documents

Publications

  • Norcliffe-Kaufmann L, Martinez J, Axelrod F, Kaufmann H. Hyperdopaminergic crises in familial dysautonomia: a randomized trial of carbidopa. Neurology. 2013 Apr 23;80(17):1611-7. doi: 10.1212/WNL.0b013e31828f18f0. Epub 2013 Apr 3. PubMed 23553478 ↗
  • Norcliffe-Kaufmann LJ, Axelrod FB, Kaufmann H. Cyclic vomiting associated with excessive dopamine in Riley-day syndrome. J Clin Gastroenterol. 2013 Feb;47(2):136-8. doi: 10.1097/MCG.0b013e3182582cbf. PubMed 22739220 ↗
  • Norcliffe-Kaufmann L, Axelrod FB, Kaufmann H. Developmental abnormalities, blood pressure variability and renal disease in Riley Day syndrome. J Hum Hypertens. 2013 Jan;27(1):51-5. doi: 10.1038/jhh.2011.107. Epub 2011 Dec 1. PubMed 22129610 ↗
  • Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2. PubMed 22045363 ↗
  • Norcliffe-Kaufmann L, Axelrod F, Kaufmann H. Afferent baroreflex failure in familial dysautonomia. Neurology. 2010 Nov 23;75(21):1904-11. doi: 10.1212/WNL.0b013e3181feb283. PubMed 21098405 ↗
  • Palma JA, Norcliffe-Kaufmann L, Fuente-Mora C, Percival L, Mendoza-Santiesteban C, Kaufmann H. Current treatments in familial dysautonomia. Expert Opin Pharmacother. 2014 Dec;15(18):2653-71. doi: 10.1517/14656566.2014.970530. Epub 2014 Oct 17. PubMed 25323828 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of May 2019 and a completion of May 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2022, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2015
First posted
Sep 17, 2015
Start
Sep 2015
Primary completionActual
May 10, 2019
CompletionActual
May 10, 2019
Results first posted
Feb 9, 2022
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02553265
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 17, 2015
Start date
Sep 2015
Primary completion
May 10, 2019
Completion
May 10, 2019
Results posted
Feb 9, 2022
Last update
Feb 9, 2022

Study contacts

Horacio C Kaufmann, MD
principal investigator · NYU School of Medicine
Lucy J Norcliffe-Kaufmann, PhD
principal investigator · NYU School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion